Valenta Pharm Took Part in the 26th All-Russian Research to Practice Conference "Stomach 2018"
On February 8, 2018, Moscow hosted the 26th All-Russian Research to Practice Conference "Stomach 2018. Metabolic Organization of the Stomach Functions".
This event welcomed the leading Russian experts and coincided with the release of the new clinical guidelines of the Russian Gastroenterological Association on the diagnosis and treatment of H. Pylori infection. The specialists discussed a wide range of issues related to the treatment of gastroenterological pathologies.
During the "New Directions and Strategy for the Development of Gastroenterological Science and Practice" symposium, held with the support of Valenta Pharm, the conference attendees got acquainted with the approaches to the clinical observations of the patient with functional dyspepsia (FD) and duodenogastric reflux (DGR). This issue was reviewed in report of E.S. Vyuchnova, Candidate of Medical Science, head of the Gastroenterology Department of the Central Clinical Hospital No. 1 of JSC Russian Railways, assistant professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology of the Faculty of Medicine of the Moscow State University of Medicine and Dentistry. She reported that the clinical components of DGR include a change in the gastric motor activity and delayed gastric emptying, which lead to a bitter taste in mouth, nausea, and sometimes vomiting. DGR often accompanies the course of biliary gastritis – a disease that occurs after stomach surgery, cholecystectomy, or in cases of an altered gastric motor activity.
E.S. Vyuchnova noted that in case of such functional diseases as FD, the change in gastric motility acts as the primary factor, and in case of an organic pathology (gastritis, peptic ulcer disease), the gastric motor activity disorder is secondary. It is manifested by a loss of the contractive activity and gastric emptying coordination. These symptoms can appear in various combinations, which often makes diagnosis and therapy more difficult.
E.S. Vyuchnova, Candidate of Medical Science, head of the Gastroenterology Department of the Central Clinical Hospital No. 1 of JSC Russian Railways, assistant professor of the Department of Propaedeutics of Internal Diseases and Gastroenterology of the Faculty of Medicine of the Moscow State University of Medicine and Dentistry: "Due to the wide occurrence of DGR and FD, the specialists became much more interested in medicines that can modulate the motor-evacuation function of the stomach and duodenum and prevent these conditions. Today, the treatment regimens for patients, in addition to the acidity reducing drugs, should include therapy that affects the sphincters tone, motility and visceral sensitivity of various parts of the gastrointestinal tract. At present, such therapy is provided by various drugs, including Trimedat® (active ingredient: trimebutine). It helps restore the disturbed digestion rhythm, eliminate abdominal pain and discomfort".
Gastroenterology is one of the key priority therapeutic areas of Valenta Pharm. The Company's strategy is aimed at the innovation development and creation of new highly effective drugs that shall help doctors to solve a wide range of therapeutic problems.